ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients, inhibits ...

Biogen Inc. (NASDAQ:BIIB), currently valued at $19.15 billion by market capitalization, reported its earnings for the fourth ...

SAN DIEGO, CA, USA I 12, 2025 I AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology ...